Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

被引：1
|
作者：
Houghton, Peter J. [1 ]
Kurmasheva, Raushan T. [1 ]
Gorlick, Richard [2 ]
Kolb, E. Anders [3 ]
Mosse, Yael P. [4 ]
Erickson, Stephen W. [5 ]
Guo, Yuelong [5 ]
Teicher, Beverly A. [6 ]
Smith, Malcolm A. [6 ]
Maris, John M. [4 ]
机构：
[1] Greehey Childrens Canc Res Inst, San Antonio, TX USA
[2] MD Anderson, Houston, TX USA
[3] Nemours Ctr Canc & Blood Disorders, Wilmington, DE USA
[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[5] RTI Int, Res Triangle Pk, NC USA
[6] NCI, Bethesda, MD 20892 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-LB-B15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-B15
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    Maris, John M.
    Courtright, Joshua
    Houghton, Peter J.
    Morton, Christopher L.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Tajbakhsh, Mayamin
    Reynolds, C. Patrick
    Keir, Stephen T.
    Wu, Jianrong
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2008, 50 (03) : 581 - 587
  • [22] Pediatric preclinical testing program (PPTP) evaluation of the DNA methylating agent temozolomide
    Keir, Stephen T.
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Caroi, Hernan
    Lock, Richard
    Kang, Min H.
    Reynolds, C. Patrick
    Maris, John M.
    Wu, Jianrong
    Smith, Malcolm A.
    Houghton, Peter J.
    CANCER RESEARCH, 2011, 71
  • [23] Pediatric preclinical testing program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171
    Smith, M. A.
    Maris, J. M.
    Keir, S. T.
    Lock, R. B.
    Gorlick, R.
    Kolb, E. A.
    Keshelava, N.
    Reynolds, C. P.
    Morton, C.
    Houghton, P. J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 34 - 35
  • [24] Antitumor effects of WEE1 inhibitor, AZD1775 alone or in combination with PARP inhibitor in triple negative breast cancer cells
    Ha, Dong Hyeon
    Min, Arrum
    Kim, Seongyeong
    Kim, So Hyeon
    Jang, Hyemin
    Kim, Yu Jin
    Jung, Daeun
    Park, YoonJung
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong Kiim
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children's Oncology Group Study (ADVL1312)
    Cole, Kristina A.
    Reid, Joel M.
    Liu, Xiaowei
    Minard, Charles G.
    Maris, John M.
    Fox, Elizabeth
    Weigel, Brenda J.
    CANCER RESEARCH, 2017, 77
  • [26] Single agent AZD 1775, a Weel inhibitor, shows activity in BRCA deficient patients
    Coyne, Geraldine OSullivan
    Kummar, Shivaani
    Takebe, Naoko
    Khanh Tu Do
    Meehan, Robert
    Piekarz, Richard
    Zlott, Jennifer
    Juwara, Lamin
    Quinn, Mary
    Sharon, Elad
    Streicher, Howard
    Rubinstein, Lawrence
    Levine, Chana
    Doroshow, James H.
    Chen, Alice P.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [27] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [28] A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer
    Cuneo, Kyle C.
    Morgan, Meredith A.
    Zalupski, Mark M.
    Sahai, Vaibhav
    Schipper, Matthew J.
    Maybaum, Jonathan
    Lawrence, Theodore S.
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Preclinical Evaluation of Bisantrene As Single Agent and in Combination with Decitabine for Acute Myeloid Leukemia
    Verrills, Nicole M.
    Murray, Heather C.
    Brzozowski, Joshua S.
    Panicker, Nikita
    Miller, Kasey
    Messina, Marinella
    Buckley, Benjamin J.
    Kelso, Michael J.
    Enjeti, Anoop K.
    BLOOD, 2023, 142
  • [30] A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
    Gonzalez-Ochoa, Eduardo
    Milosevic, Michael
    Corr, Bradley
    Abbruzzese, James L.
    Girda, Eugenia
    Miller, Rachel W.
    Croke, Jennifer
    Mackay, Helen
    Lee, Yeh Chen
    Bowering, Valerie
    Ramsahai, Janelle
    Wang, Lisa
    D'Souza, April
    Kunos, Charles A.
    Oza, Amit M.
    Lheureux, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1208 - 1214
12345